Thiogenesis Therapeutics, Corp.
TTI.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.75M | -2.29M | -3.01M | -3.31M | -3.48M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 283.20K | 253.30K | 204.60K | 245.10K | 287.10K |
| Change in Net Operating Assets | 484.70K | -843.60K | -204.80K | -67.90K | -45.20K |
| Cash from Operations | -1.98M | -2.88M | -3.01M | -3.13M | -3.24M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 260.90K | 723.40K | 4.59M | 4.58M | 4.58M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 186.50K | 529.50K | 3.38M | 3.37M | 3.37M |
| Foreign Exchange rate Adjustments | -11.10K | -22.80K | 2.30K | -15.50K | -6.90K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.80M | -2.37M | 372.20K | 222.10K | 123.50K |